Kiniksa Pharmaceuticals, Ltd.

NASDAQ:KNSA

Biotechnology

Healthcare
$95.05 +0.77%

+$0.42 today

Market cap
$7.47B
Beta
0.12
P/E (TTM)
57.2
EPS (TTM)
$0.95
52W Low $26.27High $59.87

Volume 0.33M

Average 0.66M

KNSA Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Kiniksa Pharmaceuticals, Ltd.NASDAQ: KNSA

Operating Income · Q2 FY2026 · quarter ended Jun 2026

Operating income grows, but more slowly than its trailing trend

Q2 FY2026 operating income of $27.19M rose 34.9% year over year, behind the +2140.2% change in trailing-twelve-month operating income. Sequentially, it fell 7.1% from the prior quarter. Over 3 fiscal years it compounded at +99.2% a year.

Context

  • Operating income amounted to 11.4% of revenue in FY2025, up 0.6 pp from a year earlier.
  • Operating income increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 5 analysts of $158.9M (+105.8%) for the fiscal year ending Dec 2026, a slowdown from the +269.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$27.19M-7.1% QoQ
Last fiscal yearDec 2025
$77.22M+269.3% YoY
LTMJun 2026
$100.25M+2140.2% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+34.9%+79.0%+44.1 pp
1 year+269.3%+105.8%-163.5 pp
3-year CAGR+99.2%+49.2%-50.0 pp
5-year CAGR+57.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
77.22M USD
Year-over-year change
+269.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How KNSA compares with its peers on the latest reported figures

  • KNSA's LTM Jun 2026 operating income of $100.25M is the 2nd highest of the 10 companies compared; the peer median is -$80.48M.
  • Its year-over-year change of +2140.2% is the 2nd highest of 10, against a peer median of -9.1%.
  • Operating income amounts to 11.9% of revenue for KNSA, versus a peer median of 619.2%.
KNSA Competitors Peer median
Operating Income for KNSA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$289.66M +208.4%—41.3%
KNSAKiniksa Pharmaceuticals, Ltd.LTM Jun 2026$100.25M +2140.2%+99.2%11.9%
ANABAnaptysBio, Inc.LTM Mar 2026$40.8M +140.7%—17.6%
PHARPharming Group N.V.LTM Mar 2026$23.38M +3514.0%+4.6%6.3%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-$79.16M -57.0%—134164.4%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$80.48M +43.0%—961.9%
ORKAOruka Therapeutics, Inc.LTM Sep 2026-$183.11M -45.4%——
DNTHDianthus Therapeutics, Inc.LTM Jun 2026-$217.84M -67.7%—11441.4%
SYRESpyre Therapeutics, Inc.LTM Sep 2026-$250.17M -17.1%—276.5%
IMVTImmunovant, Inc.LTM Sep 2026-$531.3M -9.1%—7488.4%
Peer median (excluding KNSA) -$80.48M-9.1%+4.6%619.2%

Competitors are the stored peer set for KNSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue38.54M220.18M270.26M423.24M677.56M
Cost of Revenue9.1M22.9M56.52M60.91M307.41M
Gross Profit29.44M197.29M213.74M362.33M370.15M
Gross Margin76.4%89.6%79.1%85.6%54.6%
Research & Development99.3M65.49M76.1M111.62M96.85M
Selling, General & Admin85.95M97.95M129.43M168.01M196.27M
Operating Expenses186.08M187.51M238.93M407.95M292.93M
Depreciation & Amortization2.36M2.4M2.34M1.7M1.55M
EBITDA(154.18M)13.43M(14.31M)(34.46M)90.42M
EBITDA Margin-400.0%6.1%-5.3%-8.1%13.3%
Operating Income(156.64M)9.77M(25.2M)(45.62M)77.22M
Operating Margin-406.4%4.4%-9.3%-10.8%11.4%
Interest Income97K1.25M8.54M9.46M11.65M
Interest Expense00000
Other Income / Expenses97K1.25M8.54M9.46M11.65M
Income Before Tax(156.54M)11.03M(16.65M)(36.15M)88.87M
Pre-Tax Margin-406.1%5.0%-6.2%-8.5%13.1%
Income Tax Expense1.39M(172.34M)(30.74M)7.04M29.86M
Net Income(157.92M)183.36M14.08M(43.19M)59.01M
Net Margin-409.7%83.3%5.2%-10.2%8.7%
EPS (Basic)(2.30)2.640.20(0.60)0.80
EPS (Diluted)(2.30)2.600.20(0.60)0.75
Weighted Avg Shares68.58M69.38M70.06M71.42M74.2M
Weighted Avg Shares (Diluted)68.58M70.42M71.92M71.42M78.98M

Kiniksa Pharmaceuticals, Ltd.

NASDAQ:KNSA

Intrinsic Alpha fair value

Locked

Current Price

$95.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.